

Emmanuel J Favaloro

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3402528/emmanuel-j-favaloro-publications-by-citations.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

630
papers

15,758
citations

55
h-index

97
g-index

702
ext. papers

18,696
ext. citations

4.6
avg, IF

7.57
L-index

#	Paper	IF	Citations
630	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2950-2973	15.1	1682
629	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 2103-14	15.4	884
628	D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 876-878	7	328
627	Clinical utility of the PFA-100. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 709-33	5.3	235
626	Characterization of GMP-140 (P-selectin) as a circulating plasma protein. <i>Journal of Experimental Medicine</i> , 1992 , 175, 1147-50	16.6	226
625	Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. <i>Clinica Chimica Acta</i> , 2020 , 507, 167-173	6.2	200
624	The paradoxical relationship between serum uric acid and cardiovascular disease. <i>Clinica Chimica Acta</i> , 2008 , 392, 1-7	6.2	162
623	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 437-450	7	159
622	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1004-1024	7	147
621	Clinical application of the PFA-100. <i>Current Opinion in Hematology</i> , 2002 , 9, 407-15	3.3	139
620	International consensus guidelines on anticardiolipin and anti- β_2 -glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1-10		137
619	Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 612-34	5.3	137
618	Quality standards for sample collection in coagulation testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 565-75	5.3	133
617	Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 59-70	5.3	122
616	Mental depression and cardiovascular disease: a multifaceted, bidirectional association. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 325-36	5.3	115
615	Quality standards for sample processing, transportation, and storage in hemostasis testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 576-85	5.3	91
614	Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. <i>Haemophilia</i> , 2001 , 7, 170-9	3.3	91

613	Obstructive sleep apnea syndrome and cardiovascular diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 280-97	5.3	90
612	Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. <i>American Journal of Clinical Pathology</i> , 2002 , 118, 548-57	1.9	84
611	Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 621-33	5.3	82
610	Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 258-66	5.3	80
609	Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis. <i>Laboratory Medicine</i> , 2012 , 43, 1.2-10	1.6	79
608	Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 440-55	5.3	78
607	Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 208-27	5.3	77
606	ABO blood group, hypercoagulability, and cardiovascular and cancer risk. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012 , 49, 137-49	9.4	76
605	Mild hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 421-32	15.4	76
604	An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 727-44	5.3	76
603	A diet rich in high-oleic-acid sunflower oil favorably alters low-density lipoprotein cholesterol, triglycerides, and factor VII coagulant activity. <i>Journal of the American Dietetic Association</i> , 2005 , 105, 1071-9		76
602	Thrombotic complications of erythropoiesis-stimulating agents. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 537-49	5.3	75
601	Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing. <i>American Journal of Clinical Pathology</i> , 2004 , 122, 686-692	1.9	74
600	Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder. <i>American Journal of Clinical Pathology</i> , 2005 , 124, 910-917	1.9	74
599	Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. <i>British Journal of Haematology</i> , 1996 , 94, 400-6	4.5	72
598	Laboratory identification of von Willebrand disease: technical and scientific perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 456-71	5.3	70
597	Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand disease. <i>Blood Coagulation and Fibrinolysis</i> , 1991 , 2, 285-91	1	70
596	Laboratory investigation of thrombophilia: the good, the bad, and the ugly. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 695-710	5.3	69

595	Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 459-71	5.1	69
594	Activated partial thromboplastin time: new tricks for an old dogma. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 604-11	5.3	69
593	Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 433-46	5.3	67
592	The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. <i>Pathology</i> , 2016 , 48, 60-71	1.6	67
591	Help me, Doctor! My D-dimer is raised. <i>Annals of Medicine</i> , 2008 , 40, 594-605	1.5	66
590	Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidimensional or multifaceted primary-hemostasis coin?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 113-27	5.3	64
589	Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 637-47	1	64
588	Contemporary platelet function testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 579-98	5.9	63
587	Laboratory testing of anticoagulants: the present and the future. <i>Pathology</i> , 2011 , 43, 682-92	1.6	62
586	Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 73-8	7	62
585	Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. <i>American Journal of Clinical Pathology</i> , 1995 , 104, 264-71	1.9	62
584	Criteria for PL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. <i>Lupus</i> , 2011 , 20, 182-90	2.6	61
583	Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. <i>Blood</i> , 2000 , 95, 164-172	2.2	61
582	Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand disease and other disorders. <i>American Journal of Hematology</i> , 1999 , 62, 165-74	7.1	61
581	Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 185-97	5.9	59
580	The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 537-45	5.3	59
579	Laboratory tests used to help diagnose von Willebrand disease: an update. <i>Pathology</i> , 2016 , 48, 303-18	1.6	59
578	The role of ethnicity, age and gender in venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 29, 489-96	5.1	58

577	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2828-2839	15.4	57
576	Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 58, 1191-1199	5.9	56
575	Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 505-13	5.3	54
574	The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study. <i>Ophthalmology</i> , 2008 , 115, 693-9	7.3	53
573	Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey. <i>Seminars in Thrombosis and Hemostasis</i> , 2002 , 28, 191-202	5.3	53
572	Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand disease. <i>Blood Reviews</i> , 1999 , 13, 185-204	11.1	53
571	Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 389-410	5.3	52
570	Internal quality control and external quality assurance of platelet function tests. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 139-49	5.3	51
569	Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 379-382	5.3	50
568	Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. <i>Thrombosis Research</i> , 2014 , 134, 1292-300	8.2	50
567	Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 1009-21	7	50
566	A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 73-84	5.3	50
565	Coronavirus Disease 2019-Associated Coagulopathy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 203-217	6.4	50
564	Differential expression of surface antigens on activated endothelium. <i>Immunology and Cell Biology</i> , 1993 , 71 (Pt 6), 571-81	5	49
563	Evaluating errors in the laboratory identification of von Willebrand disease in the real world. <i>Thrombosis Research</i> , 2014 , 134, 393-403	8.2	48
562	Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 501-8	7	47
561	Laboratory testing in disseminated intravascular coagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 458-67	5.3	47
560	Acquired inhibitors of coagulation factors: part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 447-53	5.3	47

559	von Willebrand disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy. <i>American Journal of Hematology</i> , 1994 , 45, 205-11	7.1	47
558	Venous and Arterial Thromboses: Two Sides of the Same Coin?. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 239-248	5.3	46
557	Treatment of von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 133-46	5.3	46
556	Milestones and perspectives in coagulation and hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 9-22	5.3	46
555	Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines. <i>Pathology</i> , 2014 , 46, 481-95	1.6	44
554	Standards and reference materials for the anticardiolipin and anti- β glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. <i>Clinica Chimica Acta</i> , 2012 , 413, 358-60	6.2	44
553	Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case-control study. <i>Investigative Ophthalmology and Visual Science</i> , 2007 , 48, 1983-8		44
552	The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. <i>Pathology</i> , 2015 , 47, 355-64	1.6	43
551	Clinical utility of closure times using the platelet function analyzer-100/200. <i>American Journal of Hematology</i> , 2017 , 92, 398-404	7.1	42
550	Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. <i>Annals of Translational Medicine</i> , 2017 , 5, 322	3.2	42
549	Genetic testing for von Willebrand disease: the case against. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 6-12	15.4	42
548	Standardization of the INR: how good is your laboratory's INR and can it be improved?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 593-603	5.3	42
547	Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 49-58	5.3	42
546	Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. <i>Thrombosis Research</i> , 2016 , 141, 202-11	8.2	41
545	Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. <i>Blood Coagulation and Fibrinolysis</i> , 2011 , 22, 553-64	1	41
544	Shortened activated partial thromboplastin time: causes and management. <i>Blood Coagulation and Fibrinolysis</i> , 2010 , 21, 459-63	1	41
543	Co-expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis. <i>British Journal of Haematology</i> , 1990 , 74, 385-94	4.5	41
542	Differential sensitivity of von Willebrand factor (VWF) activity assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1043-54	15.4	40

541	Prevention of venous thromboembolism: focus on mechanical prophylaxis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 237-51	5.3	40
540	Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II--Lupus anticoagulant. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 404-11	5.3	40
539	Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. <i>Blood Coagulation and Fibrinolysis</i> , 2006 , 17, 39-45	1	40
538	Consensus guidelines on anti-cardiolipin antibody testing and reporting. <i>Pathology</i> , 2004 , 36, 63-8	1.6	40
537	Harmonisation of D-dimer - A call for action. <i>Thrombosis Research</i> , 2016 , 137, 219-220	8.2	40
536	International survey on D-dimer test reporting: a call for standardization. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 287-93	5.3	39
535	E-cigarettes and cardiovascular risk: beyond science and mysticism. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 60-5	5.3	38
534	2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 346-358	7	38
533	Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. <i>Haemophilia</i> , 2001 , 7, 180-9	3.3	38
532	Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. <i>British Journal of Haematology</i> , 1988 , 69, 163-71	4.5	38
531	Therapeutic monitoring of unfractionated heparin - trials and tribulations. <i>Expert Review of Hematology</i> , 2017 , 10, 595-605	2.8	37
530	Glanzmann thrombasthenia: an update. <i>Clinica Chimica Acta</i> , 2010 , 411, 1-6	6.2	37
529	Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. <i>Blood Coagulation and Fibrinolysis</i> , 2005 , 16, 597-605	1	37
528	The new oral anticoagulants and the future of haemostasis laboratory testing. <i>Biochimica Medica</i> , 2012 , 22, 329-41	2.5	37
527	Inherited and acquired factor V deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 2011 , 22, 160-6	1	36
526	C-reactive protein and venous thromboembolism: causal or casual association?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 1693-701	5.9	36
525	Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I--Anticardiolipin and anti- β_2 -glycoprotein I antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 390-403	5.3	36
524	Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. <i>Pathology</i> , 1997 , 29, 385-91	1.6	36

523	Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. <i>British Journal of Haematology</i> , 2007 , 139, 623-6	4.5	36
522	Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 39-48	5.3	36
521	von Willebrand disease: laboratory investigation using an improved functional assay for von Willebrand factor. <i>Pathology</i> , 1993 , 25, 152-8	1.6	36
520	Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 551-70	5.3	35
519	Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 616-8	5.9	35
518	The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 644-53	5.3	35
517	Patient safety and quality in laboratory and hemostasis testing: a renewed loop?. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 553-8	5.3	35
516	A laboratory evaluation into the short activated partial thromboplastin time. <i>Blood Coagulation and Fibrinolysis</i> , 2010 , 21, 152-7	1	35
515	Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 756-65	5.3	34
514	Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options. <i>American Journal of Clinical Pathology</i> , 2000 , 114, 608-18	1.9	34
513	Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis. <i>Atherosclerosis</i> , 1999 , 142, 159-68	3.1	34
512	Epidemiological association between fasting plasma glucose and shortened APTT. <i>Clinical Biochemistry</i> , 2009 , 42, 118-20	3.5	33
511	Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?. <i>Thrombosis Research</i> , 2009 , 123, 862-8	8.2	33
510	Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample. <i>International Journal of Laboratory Hematology</i> , 2010 , 32, 132-8	2.5	33
509	Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 7-25	5.3	33
508	Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2008 , 21, 178-83		33
507	Problems and solutions in laboratory testing for hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 816-33	5.3	32
506	Venous thrombosis associated with HMG-CoA reductase inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 515-32	5.3	32

505	Unsuspected triggers of venous thromboembolism--trivial or not so trivial?. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 597-604	5.3	32
504	Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. <i>Thrombosis Research</i> , 2019 , 180, 10-19	8.2	31
503	Current and Emerging Direct Oral Anticoagulants: State-of-the-Art. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 490-501	5.3	31
502	Clinical features, diagnosis, and management of the antiphospholipid syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 295-304	5.3	31
501	Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process. <i>Haemophilia</i> , 2004 , 10, 232-42	3.3	31
500	The role of buffer anions and protons in secretion by the rabbit mandibular salivary gland. <i>Journal of Physiology</i> , 1982 , 322, 273-86	3.9	31
499	Potential indirect anti-inflammatory effects of IL-4. Stimulation of human monocytes, macrophages, and endothelial cells by IL-4 increases aminopeptidase-N activity (CD13; EC 3.4.11.2). <i>Journal of Immunology</i> , 1994 , 153, 2718-28	5.3	31
498	Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. <i>Pathology</i> , 2019 , 51, 292-300	1.6	30
497	Direct-to-consumer testing: more risks than opportunities. <i>International Journal of Clinical Practice</i> , 2011 , 65, 1221-9	2.9	30
496	Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy. <i>Biomarkers in Medicine</i> , 2011 , 5, 63-70	2.3	30
495	Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 2828-31	15.4	30
494	von Willebrand disease: laboratory aspects of diagnosis and treatment. <i>Haemophilia</i> , 2004 , 10 Suppl 4, 164-8	3.3	30
493	How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 22-35	5.3	30
492	Regulation in hemostasis and thrombosis: part I-in vitro diagnostics. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 235-49	5.3	29
491	Toward a new paradigm for the identification and functional characterization of von Willebrand disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 60-75	5.3	29
490	Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. <i>Clinica Chimica Acta</i> , 2009 , 405, 8-16	6.2	29
489	Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype?. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 520-31	5.3	29
488	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 922-930	7	29

487	A Review of beta2 -glycoprotein-I antibody testing results from a peer-driven multilaboratory quality assurance program. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 441-8	1.9	29
486	A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. <i>Pathology</i> , 2004 , 36, 182-92	1.6	29
485	Laboratory Diagnosis of von Willebrand Disorder. <i>American Journal of Clinical Pathology</i> , 2003 , 119, 882-893	1.9	29
484	Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. <i>Pathology</i> , 1999 , 31, 142-7	1.6	29
483	Heparin-induced thrombocytopenia: laboratory investigation and confirmation of diagnosis. <i>Pathology</i> , 1992 , 24, 177-83	1.6	29
482	D-Dimer Testing: Laboratory Aspects and Current Issues. <i>Methods in Molecular Biology</i> , 2017 , 1646, 91-104	1.4	28
481	Biological therapies for von Willebrand disease. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 551-64	5.4	28
480	Laboratory testing for the new oral anticoagulants: a review of current practice. <i>Pathology</i> , 2013 , 45, 435-7	1.6	27
479	Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 290-7	5.3	27
478	Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. <i>Pathology</i> , 2007 , 39, 504-11	1.6	27
477	Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges. <i>Current Drug Metabolism</i> , 2017 , 18, 598-608	3.5	27
476	Type 2M and Type 2A von Willebrand Disease: Similar but Different. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 483-97	5.3	27
475	Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. <i>Expert Review of Hematology</i> , 2015 , 8, 527-42	2.8	26
474	Sudden Cardiac and Noncardiac Death in Sports: Epidemiology, Causes, Pathogenesis, and Prevention. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 780-786	5.3	26
473	Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 794-805	5.3	26
472	Tirofiban and activated protein C synergistically inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from allogeneic islet cells exposure to human blood. <i>American Journal of Transplantation</i> , 2009 , 9, 1533-40	8.7	26
471	Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 28, 362-5	5.1	26
470	CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. <i>Experimental Hematology</i> , 1993 , 21, 1695-701	3.1	26

469	Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 559-570	2.5	26
468	Platelet Function Analyzed by Light Transmission Aggregometry. <i>Methods in Molecular Biology</i> , 2017 , 1646, 321-331	1.4	25
467	Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease. <i>American Journal of Hematology</i> , 2017 , 92, 114-118	7.1	25
466	Laboratory identification of factor inhibitors: an update. <i>Pathology</i> , 2012 , 44, 293-302	1.6	25
465	Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. <i>Pathology</i> , 2008 , 40, 58-63	1.6	25
464	Updates on improvement of human athletic performance: focus on world records in athletics. <i>British Medical Bulletin</i> , 2008 , 87, 7-15	5.4	25
463	Laboratory testing, diagnosis, and management of von Willebrand disease. Current practice in Australasia. RCPA Quality Assurance Program in Haematology Scientific Haemostasis Advisory Panel. <i>American Journal of Clinical Pathology</i> , 1999 , 112, 712-9	1.9	25
462	CD-13 (p150Naminopeptidase-N): co-expression on endothelial and haemopoietic cells with conservation of functional activity. <i>Immunology and Cell Biology</i> , 1991 , 69 (Pt 4), 253-60	5	25
461	Critical pre-examination variables in the hemostasis laboratory and their quality indicators. <i>Clinical Biochemistry</i> , 2016 , 49, 1315-1320	3.5	25
460	Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update. <i>Pathology</i> , 2017 , 49, 346-355	1.6	24
459	Type 2M von Willebrand disease - more often misidentified than correctly identified. <i>Haemophilia</i> , 2016 , 22, e145-55	3.3	24
458	Novel and emerging therapies: thrombus-targeted fibrinolysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 48-58	5.3	24
457	Rethinking the diagnosis of von Willebrand disease. <i>Thrombosis Research</i> , 2011 , 127 Suppl 2, S17-21	8.2	24
456	Hemostatic properties of the lymph: relationships with occlusion and thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 213-21	5.3	24
455	Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 2842-4	15.4	24
454	A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 361-72	5.3	24
453	Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder. <i>Best Practice and Research in Clinical Haematology</i> , 2001 , 14, 299-319	4.2	24
452	Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies. <i>Methods in Molecular Biology</i> , 2017 , 1646, 473-494	1.4	23

451	A review of the value of D-dimer testing for prediction of recurrent venous thromboembolism with increasing age. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 634-9	5.3	23
450	Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 309-21	5.9	23
449	Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program. <i>International Journal of Laboratory Hematology</i> , 2009 , 31, 398-406	2.5	23
448	Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1999-2001; author reply 2002-3	15.4	23
447	Diagnostic issues in thrombophilia: a laboratory scientist's view. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 11-6	5.3	23
446	Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 447-61	5.9	23
445	Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 400-418	5.3	23
444	Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders. <i>Haemophilia</i> , 2012 , 18 Suppl 4, 66-72	3.3	22
443	Technical evaluation of the novel preanalytical module on instrumentation laboratory ACL TOP: advancing automation in hemostasis testing. <i>Journal of the Association for Laboratory Automation</i> , 2013 , 18, 382-90		22
442	Preanalytical Issues in Hemostasis and Thrombosis Testing. <i>Methods in Molecular Biology</i> , 2017 , 1646, 29-42	1.4	22
441	Influence of residual platelet count on routine coagulation, factor VIII, and factor IX testing in postfreeze-thaw samples. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 834-9	5.3	22
440	Coagulation update: what's new in hemostasis testing?. <i>Thrombosis Research</i> , 2011 , 127 Suppl 2, S13-6	8.2	22
439	Air pollution and coagulation testing: a new source of biological variability?. <i>Thrombosis Research</i> , 2008 , 123, 50-4	8.2	22
438	How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2005 , 11, 157-62		22
437	ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. <i>International Journal of Laboratory Hematology</i> , 2021 , 43 Suppl 1, 129-136	2.5	22
436	HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia. <i>Pathology</i> , 2018 , 50, 426-436	1.6	21
435	Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 411-4	15.4	21
434	Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2013 , 35, 269-74	2.5	21

433	Monitoring Therapy during Treatment of von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 338-354	5.3	21
432	Influence of posture on routine hemostasis testing. <i>Blood Coagulation and Fibrinolysis</i> , 2015 , 26, 716-9	1	21
431	Laboratory testing in pharmacies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 943-53	5.9	21
430	Pharmacogenetics of vitamin K antagonists: useful or hype?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 503-15	5.9	21
429	Coagulopathies and thrombosis: usual and unusual causes and associations, part I. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 257-9	5.3	21
428	von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 425-426	5.3	21
427	Coffee intake and cardiovascular disease: virtue does not take center stage. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 164-77	5.3	21
426	Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 798-809	5.3	21
425	Preanalytical variables in coagulation testing. <i>Blood Coagulation and Fibrinolysis</i> , 2007 , 18, 86-9	1	21
424	Identification of von Willebrand disease type 2N (Normandy) in Australia: a cross-laboratory investigation using different methods. <i>American Journal of Clinical Pathology</i> , 2002 , 118, 269-76	1.9	21
423	Harmonizing the International Normalized Ratio (INR) : Standardization of Methods and Use of Novel Strategies to Reduce Interlaboratory Variation and Bias. <i>American Journal of Clinical Pathology</i> , 2016 , 145, 191-202	1.9	21
422	Diagnostics of Inherited Bleeding Disorders of Secondary Hemostasis: An Easy Guide for Routine Clinical Laboratories. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 471-7	5.3	21
421	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1008-1020 ²¹	7	21
420	The changing face of hemostasis testing in modern laboratories: consolidation, automation, and beyond. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 294-9	5.3	20
419	The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on fibrinolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2408-2411	15.4	20
418	Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia. <i>Blood Coagulation and Fibrinolysis</i> , 2009 , 20, 706-14	1	20
417	An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. <i>Pathology</i> , 2005 , 37, 234-8	1.6	20
416	Assessment of current diagnostic practice and efficacy in testing for von Willebrand disorder: results from the second Australasian multi-laboratory survey. <i>Blood Coagulation and Fibrinolysis</i> , 2000 , 11, 729-37	1	20

415	Endothelial Cells and Normal Circulating Haemopoietic Cells Share a Number of Surface Antigens. <i>Thrombosis and Haemostasis</i> , 1989 , 61, 217-224	7	20
414	External quality assessment/proficiency testing and internal quality control for the PFA-100 and PFA-200: an update. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 239-53	5.3	19
413	von Willebrand disease and platelet disorders. <i>Haemophilia</i> , 2014 , 20 Suppl 4, 59-64	3.3	19
412	Quality issues in laboratory haemostasis. <i>Haemophilia</i> , 2010 , 16 Suppl 5, 93-9	3.3	19
411	Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 1079-90	5.9	19
410	Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 587-590	5.3	19
409	Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor. <i>American Journal of Hematology</i> , 2001 , 66, 53-6	7.1	19
408	Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand disease. <i>British Journal of Haematology</i> , 1999 , 105, 538-541	4.5	19
407	Laboratory assessment of von Willebrand factor: differential influence of prolonged ambient temperature specimen storage on assay results. <i>Haemophilia</i> , 1996 , 2, 218-23	3.3	19
406	The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150. <i>Clinica Chimica Acta</i> , 1993 , 220, 81-90	6.2	19
405	Overview of Hemostasis and Thrombosis and Contribution of Laboratory Testing to Diagnosis and Management of Hemostasis and Thrombosis Disorders. <i>Methods in Molecular Biology</i> , 2017 , 1646, 3-27	1.4	18
404	Laboratory Testing for Von Willebrand Factor Multimers. <i>Methods in Molecular Biology</i> , 2017 , 1646, 495-511	5.1	18
403	Laboratory testing for factor inhibitors. <i>Haemophilia</i> , 2014 , 20 Suppl 4, 94-8	3.3	18
402	Laboratory Assessment of von Willebrand Factor: Altered Interpretation of Laboratory Data, and Altered Diagnosis of von Willebrand Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1997 , 3, 110-118	3.3	18
401	Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 566-76	5.3	18
400	2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease. <i>British Journal of Haematology</i> , 2006 , 135, 141-2; author reply 143	4.5	18
399	Quality in coagulation and haemostasis testing. <i>Biochemia Medica</i> , 184-199	2.5	18
398	Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 845-849	5.3	18

397	Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. <i>American Journal of Clinical Pathology</i> , 2005 , 124, 910-7	1.9	18
396	Explaining and reducing the variation in inter-laboratory reported values for International Normalised Ratio. <i>Thrombosis Research</i> , 2017 , 150, 22-29	8.2	17
395	Newer Hemostatic Agents. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 802-8	5.3	17
394	Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease. <i>Haemophilia</i> , 2018 , 24, 198-210	3.3	17
393	Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing. <i>Pathology</i> , 2017 , 49, 639-643	1.6	17
392	The Platelet Function Analyser (PFA)-100 and von Willebrand disease: a story well over 16 years in the making. <i>Haemophilia</i> , 2015 , 21, 642-5	3.3	17
391	Dangers in the practice of defensive medicine in hemostasis testing for investigation of bleeding or thrombosis: part I—routine coagulation testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 812-24	5.3	17
390	Dark chocolate: consumption for pleasure or therapy?. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 28, 482-8	5.1	17
389	Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 755-7	5.9	17
388	Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. <i>Blood Coagulation and Fibrinolysis</i> , 2009 , 20, 475-83	1	17
387	Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?. <i>Haematologica</i> , 2007 , 92, 292-6	6.6	17
386	Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 2085-8	15.4	17
385	Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: a comparison of acute myeloid leukaemia and normal bone marrow cells. <i>American Journal of Hematology</i> , 1986 , 23, 43-50	7.1	17
384	Immunophenotype of clonogenic cells in myeloid leukaemia. <i>Leukemia Research</i> , 1988 , 12, 51-9	2.7	17
383	Myeloid progenitor surface antigen identified by monoclonal antibody. <i>British Journal of Haematology</i> , 1985 , 61, 11-20	4.5	17
382	Biomedical research platforms and their influence on article submissions and journal rankings: An update. <i>Biochemia Medica</i> , 7-14	2.5	17
381	Advances in hematology. Etiology and diagnosis of acquired von Willebrand syndrome. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 20-4	0.6	17
380	Evaluation of a new commercial von Willebrand factor multimer assay. <i>Haemophilia</i> , 2017 , 23, e373-e377	3.3	16

379	Laboratory hemostasis: from biology to the bench. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1035-1045	5.9	16
378	Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study. <i>Thrombosis Research</i> , 2018 , 166, 96-105	8.2	16
377	Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb). <i>Methods in Molecular Biology</i> , 2017 , 1646, 453-460	1.4	16
376	Pearls and pitfalls in factor inhibitor assays. <i>International Journal of Laboratory Hematology</i> , 2015 , 37 Suppl 1, 52-60	2.5	16
375	Technological advances in the hemostasis laboratory. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 178-85	5.3	16
374	External quality assessment of factor VIII inhibitor assays. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 320-6	5.3	16
373	A clinical audit of congenital thrombophilia investigation in tertiary practice. <i>Pathology</i> , 2011 , 43, 266-72	1.6	16
372	2011 Eberhard F. Mammen Award Announcements. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 431-439	5.3	16
371	Diagnosis and management of von Willebrand disease in Australia. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 542-54	5.3	16
370	Inherited disorders of blood coagulation. <i>Annals of Medicine</i> , 2012 , 44, 405-18	1.5	16
369	Influence of mechanical trauma of blood and hemolysis on PFA-100 testing. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 82-6	1	16
368	Welcome to a Special Issue of <i>Seminars in Thrombosis and Hemostasis</i> – The Closing Issue for 2008. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 693-695	5.3	16
367	Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group. <i>Medical Journal of Australia</i> , 2019 , 210, 509-516	4	15
366	International normalized ratio monitoring of vitamin K antagonist therapy: comparative performance of point-of-care and laboratory-derived testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 279-86	5.3	15
365	Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013 , 51, 91-7	5.9	15
364	Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 558-69	5.3	15
363	The Journal Impact Factor: don't expect its demise any time soon. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 1319-24	5.9	15
362	The spectrum of coagulation abnormalities in thyroid disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 7-10	5.3	15

361	Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1. <i>British Journal of Haematology</i> , 1995 , 89, 582-8	4.5	15
360	Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 859-862	5.3	15
359	Danger of false negative (exclusion) or false positive (diagnosis) for congenital thrombophilia in the age of anticoagulants. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 873-882	5.9	15
358	Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 264-274	5.3	15
357	Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand's Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 127-35	7	15
356	Interference from heterophilic antibodies in D-dimer assessment. A case report. <i>Blood Coagulation and Fibrinolysis</i> , 2014 , 25, 277-9	1	14
355	Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity. <i>International Journal of Laboratory Hematology</i> , 2013 , 35, 170-6	2.5	14
354	Rare bleeding disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 345-7	5.3	14
353	External quality assurance for heparin monitoring. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 632-9	5.3	14
352	2012 Eberhard F. Mammen Award Announcements. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 425-432	5.3	14
351	Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients--a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 2280-2; author reply 2283-5	15.4	14
350	Platelet function testing in pediatric patients. <i>Expert Review of Hematology</i> , 2017 , 10, 281-288	2.8	13
349	Managing the patient identification crisis in healthcare and laboratory medicine. <i>Clinical Biochemistry</i> , 2017 , 50, 562-567	3.5	13
348	Sodium citrate blood contamination by K2 -ethylenediaminetetraacetic acid (EDTA): impact on routine coagulation testing. <i>International Journal of Laboratory Hematology</i> , 2015 , 37, 403-9	2.5	13
347	The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. <i>International Journal of Laboratory Hematology</i> , 2020 , 42 Suppl 1, 41-48	2.5	13
346	Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies. <i>Haemophilia</i> , 2020 , 26, 503-512	3.3	13
345	The futility of thrombophilia testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014 , 52, 499-503	5.9	13
344	A novel flow cytometry single tube bead assay for quantitation of von Willebrand factor antigen and collagen-binding. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 999-1005	7	13

343	Sample collection and platelet function testing: influence of vacuum or aspiration principle on PFA-100 test results. <i>Blood Coagulation and Fibrinolysis</i> , 2013 , 24, 666-9	1	13
342	Influenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both?. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 49-58	5.3	13
341	Prostate-specific antigen, prostate cancer, and disorders of hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 654-64	5.3	13
340	Holiday thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 869-74	5.3	13
339	D-dimer measurement and laboratory feedback. <i>Journal of Emergency Medicine</i> , 2009 , 37, 82-3; author reply 83	1.5	13
338	The MDA-180 coagulation analyser: a laboratory evaluation. <i>Pathology</i> , 1997 , 29, 176-83	1.6	13
337	A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. <i>Pathology</i> , 2002 , 34, 348-55	1.6	13
336	Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin deficiency and the potential high risk of a false positive diagnosis. <i>Laboratory Hematology: Official Publication of the International</i>		13
335	Dark chocolate modulates platelet function with a mechanism mediated by flavan-3-ol metabolites. <i>Medicine (United States)</i> , 2018 , 97, e13432	1.8	13
334	Critical laboratory values in hemostasis: toward consensus. <i>Annals of Medicine</i> , 2017 , 49, 455-461	1.5	12
333	Diagnostics in venous thromboembolism: from origin to future prospects. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 374-81	5.3	12
332	Anticoagulation at the extremes of body weight: choices and dosing. <i>Expert Review of Hematology</i> , 2018 , 11, 817-828	2.8	12
331	Thrombophilia testing in patients taking direct oral anticoagulants. Handle with care. <i>Diagnosis</i> , 2014 , 1, 311-312	4.2	12
330	Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2014 , 25, 292-5	1	12
329	Antisense therapy in the treatment of hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 2011 , 22, 541-6	3.9	12
328	Coagulopathies and thrombosis: usual and unusual causes and associations, Part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 591-5	5.3	12
327	Diagnostic evaluation of platelet disorders: the past, the present, and the future. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 127-30	5.3	12
326	A tribute to Eberhard F. Mammen, M.D. (1930-2008). <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 703-7	5.3	12

325	Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 85-9	5.3	12
324	Characterization of a p43 human thymocyte antigen. <i>Disease Markers</i> , 1986 , 4, 261-70	3.2	12
323	Haemolysis index for the screening of intravascular haemolysis: a novel diagnostic opportunity?. <i>Blood Transfusion</i> , 2018 , 16, 433-437	3.6	12
322	Filtered plasma as a potential cause of clinical misdiagnosis: inappropriate testing in a haematology laboratory. <i>British Journal of Biomedical Science</i> , 1995 , 52, 243-8	1.6	12
321	Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 228-246	5.3	11
320	Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. <i>Internal Medicine Journal</i> , 2019 , 49, 59-65	1.6	11
319	How to Generate a More Accurate Laboratory-Based International Normalized Ratio: Solutions to Obtaining or Verifying the Mean Normal Prothrombin Time and International Sensitivity Index. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 10-21	5.3	11
318	The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA). <i>American Journal of Hematology</i> , 2019 , 94, 1290-1296	7.1	11
317	Semi-automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, 762-771	2.5	11
316	Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing. <i>Methods in Molecular Biology</i> , 2017 , 1646, 391-402	1.4	11
315	Recent advances in laboratory-aided diagnosis of von Willebrand disease. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 975-995	1.1	11
314	2013 Eberhard F. Mammen Award Announcements. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 567-574	5.3	11
313	The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?. <i>Autoimmunity Highlights</i> , 2010 , 1, 5-14	3.7	11
312	Time to think outside the box? Prothrombin time, international normalised ratio, international sensitivity index, mean normal prothrombin time and measurement of uncertainty: a novel approach to standardisation. <i>Pathology</i> , 2008 , 40, 277-87	1.6	11
311	Activated protein C resistance: the influence of ABO-blood group, gender and age. <i>Thrombosis Research</i> , 2006 , 117, 665-70	8.2	11
310	A duplex issue: (i) time to re-appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays. <i>Haemophilia</i> , 2002 , 8, 828-31	3.3	11
309	Towards personalised therapy for von Willebrand disease: a future role for recombinant products. <i>Blood Transfusion</i> , 2016 , 14, 262-76	3.6	11
308	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part I. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 757-762	5.3	11

307	Characterizing the Mechanistic Pathways of the Instant Blood-Mediated Inflammatory Reaction in Xenogeneic Neonatal Islet Cell Transplantation. <i>Transplantation Direct</i> , 2016 , 2, e77	2.3	11
306	Platelet Transfusion Thresholds: How Low Can We Go in Respect to Platelet Counting?. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 238-244	5.3	11
305	Time dependent reduction in platelet aggregation using the multiplate analyser and hirudin blood due to platelet clumping. <i>Platelets</i> , 2018 , 29, 305-308	3.6	11
304	Analytical Assessment of the New Roche Cobas t 711 Fully Automated Coagulation Analyzer. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 308-314	5.3	10
303	To Maintain or Cease Non-Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 171-179	5.3	10
302	Anticoagulant therapy: present and future. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 109-12	5.3	10
301	Article downloads and citations: is there any relationship?. <i>Clinica Chimica Acta</i> , 2013 , 415, 195	6.2	10
300	Potential misdiagnosis of von Willebrand disease and haemophilia caused by ineffective mixing of thawed plasma. <i>Haemophilia</i> , 2017 , 23, e436-e443	3.3	10
299	Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. <i>Haemophilia</i> , 2010 , 16, 662-70	3.3	10
298	Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 203-7	1	10
297	Cardiac biomarkers in pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 1134-6	7	10
296	The missing link between genotype, phenotype and clinics. <i>Biochemia Medica</i> , 137-145	2.5	10
295	Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. <i>Pathology</i> , 1985 , 17, 392-9	1.6	10
294	Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). <i>Clinical Chemistry and Laboratory Medicine</i> , 2022 , 60, 7-17	5.9	10
293	COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 ,	5.3	10
292	Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays. <i>British Journal of Biomedical Science</i> , 1999 , 56, 23-33	1.6	10
291	Next generation antithrombotic therapy: focus on antisense therapy against coagulation factor XI. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 255-62	5.3	9
290	Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 278-284	5.1	9

289	Mixing of thawed coagulation samples prior to testing: Is any technique better than another?. <i>Clinical Biochemistry</i> , 2016 , 49, 1399-1401	3.5	9
288	Gender related issues in thrombosis and hemostasis. <i>Expert Review of Hematology</i> , 2017 , 10, 941-949	2.8	9
287	Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB). <i>Methods in Molecular Biology</i> , 2017 , 1646, 417-433	1.4	9
286	A short history of Thrombosis and Hemostasis: part I (40th year celebratory issue). <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 521-5	5.3	9
285	Coagulopathies and thrombosis: usual and unusual causes and associations, Part IV. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 175-80	5.3	9
284	Acquired functional coagulation inhibitors: review on epidemiology, results of a wet-workshop on laboratory detection, and implications for quality of inhibitor diagnosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 613-21	5.3	9
283	The genetic basis of human athletic performance. Why are psychological components so often overlooked?. <i>Journal of Physiology</i> , 2008 , 586, 3017; author reply 3019-20	3.9	9
282	Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 745-58	5.3	9
281	Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 235-42	5.3	9
280	Evaluation of primary haemostasis in people with neurofibromatosis type 1. <i>International Journal of Laboratory Hematology</i> , 2004 , 26, 341-5		9
279	Medical research in New South Wales 1993-1996 assessed by Medline publication capture. <i>Medical Journal of Australia</i> , 1998 , 169, 617-22	4	9
278	Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2005 , 11, 91-7		9
277	Platelet Function Testing: Auditing Local Practice and Broader Implications. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2010 , 23, 21-31		9
276	Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 ,	5.3	9
275	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 922-30	7	9
274	The Intriguing Link between the Intestinal Microbiota and Cardiovascular Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 609-613	5.3	8
273	Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1784-1789	5.9	8
272	Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making. <i>Thrombosis Research</i> , 2020 , 188, 17-24	8.2	8

271	Laboratory Testing for Activated Protein C Resistance (APCR). <i>Methods in Molecular Biology</i> , 2017 , 1646, 137-143	1.4	8
270	Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag). <i>Methods in Molecular Biology</i> , 2017 , 1646, 403-416	1.4	8
269	Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo). <i>Methods in Molecular Biology</i> , 2017 , 1646, 435-451	1.4	8
268	Toward improved diagnosis of HIT. <i>Blood</i> , 2015 , 126, 563-4	2.2	8
267	2014 Eberhard F. Mammen Award announcements: Part I--Most popular articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 407-12	5.3	8
266	Discard tubes are sometimes necessary when drawing samples for hemostasis. <i>American Journal of Clinical Pathology</i> , 2010 , 134, 851	1.9	8
265	Platelets, inflammation and cardiovascular diseases. New concepts and therapeutic implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 129-30	5.3	8
264	Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey. <i>Pathology</i> , 2009 , 41, 666-75	1.6	8
263	Antiphospholipid antibodies and the antiphospholipid syndrome. I: pathogenesis, clinical features, diagnosis, and management. Preface. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 213-8	5.3	8
262	Potential benefits of improved protein intake in older people. <i>Nutrition and Dietetics</i> , 2008 , 65, 151-156	2.5	8
261	Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand. <i>Blood Coagulation and Fibrinolysis</i> , 2007 , 18, 441-8	1	8
260	Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. <i>American Journal of Clinical Pathology</i> , 2004 , 122, 686-92	1.9	8
259	Standardization of monoclonal antibodies for use in autologous bone marrow transplantation for common acute lymphoblastic leukemia. <i>Pathology</i> , 1986 , 18, 197-205	1.6	8
258	Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests. <i>American Journal of Hematology</i> , 2020 , 95, 117-128	7.1	8
257	International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 398-409	5.3	8
256	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19): Part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 333-337	5.3	8
255	Why Do Patients Bleed?. <i>The Surgery Journal</i> , 2016 , 2, e29-e43	0.9	8
254	The increasing maturity of the von Willebrand factor collagen binding in von Willebrand disease diagnosis. <i>Haemophilia</i> , 2018 , 24, 20-23	3.3	8

253	Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?. <i>American Journal of Hematology</i> , 2018 , 93, 308-314	7.1	8
252	Oral anticoagulants around the world: an updated state-of-the art analysis. <i>Annals of Blood</i> , 2018 , 3, 49-496		8
251	Statins and other drugs: Facing COVID-19 as a vascular disease. <i>Pharmacological Research</i> , 2020 , 159, 105033	10.2	7
250	Navigating the Myriad of von Willebrand Factor Assays. <i>Hamostaseologie</i> , 2020 , 40, 431-442	1.9	7
249	Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. <i>Haemophilia</i> , 2020 , 26, 354-362	3.3	7
248	2018 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 185-192	5.3	7
247	Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 784-792	5.3	7
246	2B or not 2B? Masquerading as von Willebrand disease?. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 317-9	15.4	7
245	Optimizing the Verification of Mean Normal Prothrombin Time (MNPT) and International Sensitivity Index (ISI) for Accurate Conversion of Prothrombin Time (PT) to International Normalized Ratio (INR). <i>Methods in Molecular Biology</i> , 2017 , 1646, 59-74	1.4	7
244	Response to "Comment on N^{e} -cigarettes and cardiovascular risk: beyond science and mysticism N^{e} . <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 519-20	5.3	7
243	A short history of thrombosis and hemostasis: part II (40th year celebratory issue). <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 826-30	5.3	7
242	Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 360-6	5.1	7
241	Massive posttraumatic bleeding: epidemiology, causes, clinical features, and therapeutic management. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 83-93	5.3	7
240	Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 220-2 ^{15.4}	15.4	7
239	External quality assurance for the PFA-100 \square . <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 878-80	15.4	7
238	A robust method for testing urinary iodine using a microtitre robotic system. <i>Journal of Trace Elements in Medicine and Biology</i> , 2011 , 25, 213-7	4.1	7
237	Proficiency testing/external quality assurance for the PFA-100(\square). <i>Clinical Chemistry and Laboratory Medicine</i> , 2012 , 50, 1393-401	5.9	7
236	Differential identification of PT-VWD from type 2B VWD and GP1BA nomenclature issues response to Othman. <i>British Journal of Haematology</i> , 2008 , 142, 314-315	4.5	7

235	Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardization, and clinical utility of laboratory testing. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 309-12	5.3	7
234	2B or not 2B? Differential identification of type 2B, versus pseudo-, von Willebrand disease □ response to Whalley and Perry. <i>British Journal of Haematology</i> , 2007 , 136, 345-346	4.5	7
233	More on N universal N ersus N selected N creening for thrombophilia: the hidden costs of false-positive diagnosis. <i>British Journal of Haematology</i> , 2006 , 134, 239-40; author reply 241	4.5	7
232	Sulfatide-binding assay for von Willebrand factor. Detection of von Willebrand N disease without discrimination of vWD subtypes. <i>Thrombosis Research</i> , 2000 , 98, 213-9	8.2	7
231	Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, Mp67N (CD-33). <i>Disease Markers</i> , 1987 , 5, 215-25	3.2	7
230	2020 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 383-392	5.3	7
229	The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 547-558	2.5	7
228	Allergy and Venous Thromboembolism: A Casual or Causative Association. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 63-8	5.3	7
227	Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A. <i>Advances in Clinical Chemistry</i> , 2019 , 88, 151-167	5.8	7
226	Understanding the "philosophy" of laboratory hemostasis. <i>Diagnosis</i> , 2019 , 6, 223-226	4.2	7
225	A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia. <i>Pathology</i> , 2021 , 53, 247-256	1.6	7
224	Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 21-28	2.5	7
223	Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 451-455	5.3	7
222	Anticoagulation therapy in Australia. <i>Annals of Blood</i> , 2018 , 3, 48-48	0.6	7
221	e-thrombosis: epidemiology, physiopathology and rationale for preventing computer-related thrombosis. <i>Annals of Translational Medicine</i> , 2018 , 6, 344	3.2	7
220	An update on quality control for the PFA-100/PFA-200. <i>Platelets</i> , 2018 , 29, 622-627	3.6	7
219	2017 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 357-363	5.3	6
218	Towards harmonization of external quality assessment/proficiency testing in hemostasis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 57, 115-126	5.9	6

217	Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene "Mutation" (G20210A). <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 730-742	5.3	6
216	Laboratory Testing Protocols for Heparin-Induced Thrombocytopenia (HIT) Testing. <i>Methods in Molecular Biology</i> , 2017 , 1646, 227-243	1.4	6
215	Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD). <i>Methods in Molecular Biology</i> , 2017 , 1646, 461-472	1.4	6
214	Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 367-73	5.1	6
213	Lupus anticoagulant testing--sometimes mixing is required: potential for false negatives without mixing studies. <i>Blood Coagulation and Fibrinolysis</i> , 2013 , 24, 673-6	1	6
212	Laboratory medicine and natural disasters: are we ready for the challenge?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 573-5	5.9	6
211	Recombinants in thrombosis and hemostasis: from basic research to clinical therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 471-6	5.3	6
210	Venous thromboembolism in chronic liver disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 66-76	5.3	6
209	Coagulopathies and thrombosis: usual and unusual causes and associations. Part V. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 859-62	5.3	6
208	Iodine Deficiency: Current Aspects and Future Prospects. <i>Laboratory Medicine</i> , 2011 , 42, 744-746	1.6	6
207	Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 1965-73	5.9	6
206	Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP. <i>Pathology</i> , 2012 , 44, 240-7	1.6	6
205	High rate of deficiency in the amino acids tryptophan and histidine in people with wounds: implication for nutrient targeting in wound management--a pilot study. <i>Advances in Skin and Wound Care</i> , 2009 , 22, 79-82	1.5	6
204	Aspirin Responsiveness, Nonresponsiveness, or Resistance: A putative role for von Willebrand factor?. <i>Blood Coagulation and Fibrinolysis</i> , 2008 , 19, 823-4	1	6
203	The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1434-5; author reply 1435-7	15.4	6
202	Type 2B von Willebrand disease in thirteen individuals from five unrelated Australian families: phenotype and genotype correlations. <i>American Journal of Hematology</i> , 2000 , 63, 197-9	7.1	6
201	Impact of experimental hypercalcemia on routine haemostasis testing. <i>PLoS ONE</i> , 2017 , 12, e0175094	3.7	6
200	Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 58, 1322-1331	5.9	6

- 199 Improving the Inter-Laboratory Harmonization of the International Normalized Ratio (INR): Utilizing the Concept of Transference to Estimate and/or Validate International Sensitivity Index (ISI) and Mean Normal Prothrombin Time (MNPT) Values and/or to Eliminate Measurement Bias. *Clinical Laboratory Science: Journal of the American Society for Medical Technology*, **2012**, 25, 13-25 6
- 198 Andexanet: Effectively Reversing Anticoagulation. *Trends in Pharmacological Sciences*, **2016**, 37, 413-414 3.2 6
- 197 Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview. *Seminars in Thrombosis and Hemostasis*, **2019**, 45, 157-163 5.3 6
- 196 Rare forms of von Willebrand disease. *Annals of Translational Medicine*, **2018**, 6, 345 3.2 6
- 195 Novel (Oral) Anticoagulant Challenges in Surgery. *Seminars in Thrombosis and Hemostasis*, **2017**, 43, 706-715 3.5 5
- 194 Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives. *European Journal of Internal Medicine*, **2020**, 76, 8-13 3.9 5
- 193 Laboratory monitoring of warfarin in the era of direct oral anticoagulants. *Lancet Haematology*, **2015**, 2, e223-4 14.6 5
- 192 Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations. *Internal Medicine Journal*, **2012**, 42, 427-34 1.6 5
- 191 Comparative sensitivity of commercially available aPTT reagents to mulga snake (*Pseudechis australis*) venom. *Pathology*, **2014**, 46, 444-9 1.6 5
- 190 Distinguishing types 1 and 2M von Willebrand disease. *International Journal of Laboratory Hematology*, **2012**, 34, 102-5 2.5 5
- 189 Diagnosis of type 1 vs. 2A and 2M von Willebrand disease. *Haemophilia*, **2012**, 18, e9-11 3.3 5
- 188 Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 767-74 5.9 5
- 187 Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease. *Thrombosis Research*, **2011**, 127, 161-6 8.2 5
- 186 Von Willebrand factor assay proficiency testing continued. *American Journal of Clinical Pathology*, **2011**, 136, 657-9 1.9 5
- 185 Quality in hemostasis and thrombosis--part I. *Seminars in Thrombosis and Hemostasis*, **2012**, 38, 549-52 5.3 5
- 184 2B or not 2B? What is the role of VWF in platelet-matrix interactions? And what is the role of the VWF:CB in VWD diagnostics? These are the questions. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 892-4 15.4 5
- 183 Laboratory diagnosis of von Willebrand disorder. Current practice in the southern hemisphere. *American Journal of Clinical Pathology*, **2003**, 119, 882-93 1.9 5
- 182 Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V Leiden and prothrombin G20210A. *American Journal of Hematology*, **1999**, 62, 199-200 7.1 5

181	Aminopeptidase-N (CD13; gp 150): contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia. <i>Leukemia Research</i> , 1995 , 19, 659-66	2.7	5
180	A survey of heparin monitoring in Australasia. <i>Pathology</i> , 1996 , 28, 343-7	1.6	5
179	Transplantation of monoclonal antibody-purged autologous bone marrow for treatment of poor risk common acute lymphoblastic leukemia. <i>Australian and New Zealand Journal of Medicine</i> , 1987 , 17, 283-9		5
178	Mean platelet volume in arterial and venous thrombotic disorders. <i>Journal of Laboratory Medicine</i> , 2020 , 44, 305-312	0.9	5
177	Futility of testing for factor V Leiden. <i>Blood Transfusion</i> , 2012 , 10, 260-3	3.6	5
176	Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 952-957	5.1	5
175	Mean Platelet Volume Predicts Severe COVID-19 Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 456-459	5.3	5
174	Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data. <i>Drugs in Context</i> , 2016 , 5, 212292	5.2	5
173	Car Travel-Related Thrombosis: Fact or Fiction?. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 327-333	3.3	5
172	Evaluating errors in the laboratory identification of von Willebrand disease using contemporary von Willebrand factor assays. <i>Pathology</i> , 2021 ,	1.6	5
171	Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand disease and other disorders 1999 , 62, 165		5
170	Laboratory testing for von Willebrand disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 1276-82	7	5
169	Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. <i>Thrombosis and Haemostasis</i> , 2000 , 84, 541-7	7	5
168	A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates. <i>Thrombosis and Haemostasis</i> , 2002 , 87, 466-76	7	5
167	Statins for Preventing Venous Thrombosis: For or Against?. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 834-836	5.3	4
166	Editorial Compilation V. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 193-196	5.3	4
165	Lack of grading agreement among international hemostasis external quality assessment programs. <i>Blood Coagulation and Fibrinolysis</i> , 2018 , 29, 111-119	1	4
164	Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 747-755	5.3	4

163	Development and implementation of an expert rule set for automated reflex testing and validation of routine coagulation tests in a large pathology network. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, 642-649	2.5	4
162	The effect of hyperglycaemia on haemostasis testing--a volunteer study. <i>Anaesthesia</i> , 2015 , 70, 549-54	6.6	4
161	Still more discussion on the journal impact factor. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013 , 51, e283-4	5.9	4
160	Prevalence of hypokalaemia: the experience of a large academic hospital. <i>Internal Medicine Journal</i> , 2010 , 40, 315-6	1.6	4
159	Proteomic analysis of venous thromboembolism. <i>Expert Review of Proteomics</i> , 2010 , 7, 275-82	4.2	4
158	Coagulopathies and thrombosis: usual and unusual causes and associations, part III. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 1-5	5.3	4
157	Hemolytic uremic syndrome. Preface. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 573-4	5.3	4
156	Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens. <i>Thrombosis and Haemostasis</i> , 1989 , 61, 217-24	7	4
155	The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	4
154	Analytical performance of the new D-dimer and antithrombin assay on Roche cobas t 711 analyzer. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, e54-e56	2.5	4
153	How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. <i>Haemophilia</i> , 2021 , 27, 137-148	3.3	4
152	A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 417-428	15.4	4
151	Hemostasis practice: state-of-the-art. <i>Journal of Laboratory and Precision Medicine</i> , 2018 , 3, 67-67	1.1	4
150	Rethinking internal quality control and external quality assessment for laboratory diagnostics of von Willebrand disease. <i>Annals of Blood</i> , 2019 , 4, 4-4	0.6	3
149	2019 Eberhard F. Mammen Award Announcements: Part II Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 105-113	5.3	3
148	Recent initiatives in harmonization of hemostasis practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1608-1619	5.9	3
147	A 2018 Update on the Editorial and Publication Policy of Seminars in Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 307-311	5.3	3
146	Post-analytical Issues in Hemostasis and Thrombosis Testing. <i>Methods in Molecular Biology</i> , 2017 , 1646, 545-559	1.4	3

145	Reference ranges in hemostasis testing: necessary but imperfect. <i>Journal of Laboratory and Precision Medicine</i> , 2017 , 2, 18-18	1.1	3
144	"Bleeding in the jungle". <i>American Journal of Hematology</i> , 2015 , 90, 843-6	7.1	3
143	Quality in hemostasis and thrombosis--part III. Preface. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 140-5	5.3	3
142	Quality in hemostasis and thrombosis, part II. <i>Seminars in Thrombosis and Hemostasis</i> , 2013 , 39, 229-32	5.3	3
141	Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country?. <i>Pathology</i> , 2011 , 43, 397-402	1.6	3
140	Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. <i>Neurology</i> , 2010 , 74, 1477; author reply 1477-8	6.5	3
139	Identification, pathogenesis, and treatment of factor inhibitors. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 719-22	5.3	3
138	More on preanalytical variables affecting platelet function testing using light transmittance aggregometry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 737-9	5.9	3
137	Coagulopathies and thrombosis: usual and unusual causes and associations, part VI. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 125-8	5.3	3
136	The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 299-304	5.3	3
135	Discard tube for coagulation testing: the debate continues. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 572-3	1	3
134	Problems in laboratory testing: hemophilia and beyond. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1119-20	15.4	3
133	A simple, whole blood method for assessment of platelet function: application to dietary intervention. <i>Thrombosis Research</i> , 1998 , 90, 163-9	8.2	3
132	Detection of duplicates and redundancies. A major responsibility of peer-reviewers?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 1796-7	5.9	3
131	More on: platelet function analyser (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 2099-100	15.4	3
130	Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part III.. <i>Seminars in Thrombosis and Hemostasis</i> , 2022 , 48, 3-7	5.3	3
129	A better approach to monitoring of therapy in von Willebrand disease?. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 371-373	7	3
128	The changing face of activated protein C resistance testing—10-year retrospective. <i>Annals of Blood</i> , 2015 , 5, 6-6	0.6	3

127	Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 ,	5.3	3
126	Commentary on "ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD": reflections based on recent contemporary test data. <i>Blood Advances</i> , 2021 ,	7.8	3
125	Oral anticoagulation therapy: an update on usage, costs and associated risks. <i>Pathology</i> , 2020 , 52, 736-741	1.6	3
124	2021 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 467-476	5.3	3
123	Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond. <i>American Journal of Hematology</i> , 2021 , 96, 1049-1055	7.1	3
122	Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, e413-e415	5.9	3
121	Serum Concentration of Growth Differentiation Factor-15 Is Independently Associated with Global Platelet Function and Higher Fibrinogen Values in Adult Healthy Subjects. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 621-628	5.3	2
120	Vascular Disease and Dementia: Lipoprotein(a) as a Neglected Link. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 544-547	5.3	2
119	Novel approaches to quality control and external quality assessment for platelet function testing with a focus on the platelet function analyser (PFA-100 and PFA-200). <i>Annals of Blood</i> , 2019 , 4, 3-3	0.6	2
118	2018 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 123-129	5.3	2
117	Quality in hemostasis and thrombosis - part IV. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 263-6	5.3	2
116	2017 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 81-88	5.3	2
115	Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation. <i>Haemophilia</i> , 2018 , 24, e148-e152	3.3	2
114	Postanalytical considerations that may improve the diagnosis or exclusion of haemophilia and von Willebrand disease. <i>Haemophilia</i> , 2018 , 24, 849-861	3.3	2
113	von Willebrand Disease 2018 , 57-102		2
112	A diagnosis of von Willebrand disease despite normal test results for factor VIII and von Willebrand factor antigen and activity. <i>American Journal of Hematology</i> , 2019 , 94, 1425-1432	7.1	2
111	Coagulation studies: achieving the right mix in a large laboratory network. <i>Pathology</i> , 2019 , 51, 718-722	1.6	2
110	Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1455-8; author reply 1458-60	15.4	2

109	New developments in the diagnosis and treatment of von Willebrand disease. <i>Clinical Investigation</i> , 2012 , 2, 781-795		2
108	Seminars in Thrombosis and Hemostasis. Foreword. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 803-4	5.3	2
107	Farewell to 2010!. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 797-802	5.3	2
106	2009 Eberhard F. Mammen Young Investigator Award Winners. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 469-470	5.3	2
105	Time to seek further clarity in the molecular analysis of von Willebrand disease?. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 175-7	7	2
104	Laboratory diagnostics and therapy in thrombosis and hemostasis: from bedside to bench to bedside. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 3-8	5.3	2
103	Hot topics III. Preface. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 1-4	5.3	2
102	Relationship between 24-h air pollution, emergency department admission and diagnosis of acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 29, 381-6	5.1	2
101	A practical approach to instrument selection, evaluation, basic financial management and implementation in pathology and research. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 1223-9	5.9	2
100	Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: only a part of the story. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 1122-3; author reply 1123	7	2
99	von Willebrand disease, type 2B: A diagnosis more elusive than previously thought. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 630-1; author reply 632-3	7	2
98	Effect of overnight 4 degrees C storage of whole blood on von Willebrand factor. <i>Transfusion</i> , 2006 , 46, 1057-9; author reply 1059-60	2.9	2
97	Further studies on the heterogeneity of antigens recognised by CD-1 monoclonal antibodies: distribution of epitopes and analysis of serological binding patterns. <i>Immunology and Cell Biology</i> , 1987 , 65 (Pt 6), 517-27	5	2
96	New STH (2020) Impact Factor, Most Highly Cited Papers, and Other Journal Metrics. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 745-753	5.3	2
95	Welcome to Seminars in Thrombosis and Hemostasis 2020 New (2018) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 001-005	5.3	2
94	Periodontal Disease and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 110-111	5.3	2
93	Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?. <i>Blood Coagulation and Fibrinolysis</i> , 2020 , 31, 237-242	1	2
92	Direct Oral Anticoagulants for Disseminated Intravascular Coagulation: An Alliterative Wordplay or Potentially Valuable Therapeutic Interventions?. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 457-464	5.3	2

91	Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all. <i>Blood Coagulation and Fibrinolysis</i> , 2020 , 31, 339-345	1	2
90	"Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendation from the women's SSC of the ISTH": Response to comment from Kitchen et al. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2420-2422	15.4	2
89	Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment. <i>Expert Review of Hematology</i> , 2021 , 14, 335-346	2.8	2
88	2020 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 229-237	5.3	2
87	Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study). <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	2
86	Commentary: Controversies in Thrombosis and Hemostasis Part 1-Hematidrosis: "Blood, Sweat and Fears" or A "Pigment of Fertile Imaginations?". <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 296-297	5.3	2
85	The impact factor and journals in laboratory medicine. <i>Clinical Laboratory</i> , 2009 , 55, 49-52	2	2
84	Impact of low volume citrate tubes on results of first-line hemostasis testing. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, 472-477	2.5	1
83	Not as sweet as honey: A rare case of an apparent factor V "inhibitor" in association with bee sting anaphylaxis. <i>American Journal of Hematology</i> , 2018 , 93, 965-970	7.1	1
82	Causes of Errors in Medical Laboratories 2013 , 22-31		1
81	Reflections on the next generation of hemostasis instrumentation. A glimpse into the future?. <i>Laboratoriums Medizin</i> , 2015 ,		1
80	Problems and Solutions in Laboratory Testing for Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 135-135	5.3	1
79	Laboratory Diagnosis of von Willebrand Disease: The Phenotype 2011 , 100-113		1
78	Laboratory diagnostics and appropriate care of people with haemophilia. <i>Haemophilia</i> , 2011 , 17, 824-5	3.3	1
77	Assessment for antithrombin deficiency in the real world. <i>International Journal of Laboratory Hematology</i> , 2011 , 33, 656-8; author reply 659-60	2.5	1
76	Thrombocytopenic platelet disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 615-6	5.3	1
75	Thrombotic and hemorrhagic syndromes associated with autoimmunity and infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 421-4	5.3	1
74	Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3?. <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 545-6	15.4	1

73	Protein Z is reduced in chronic kidney disease and not elevated in patients on haemodialysis. <i>Blood Coagulation and Fibrinolysis</i> , 2008 , 19, 23-5	1	1
72	Salbutamol in athletes. <i>Clinical Journal of Sport Medicine</i> , 2008 , 18, 469; author reply 469-70	3.2	1
71	Increased propensity to bruising in red-haired females: a possible role for von Willebrand factor?. <i>Anesthesia and Analgesia</i> , 2006 , 103, 1622-3	3.9	1
70	Unrecognized pellagra masquerading as odynophagia. <i>Internal Medicine Journal</i> , 2006 , 36, 472-4	1.6	1
69	Is elevated factor VIII a risk factor for venous thromboembolism in Canada?. <i>Thrombosis and Haemostasis</i> , 2005 , 94, 1112-3	7	1
68	Troubleshooting an isolate prolongation of activated partial thromboplastin time in a patient with acute myocardial infarction-a paradigmatic case report. <i>Annals of Translational Medicine</i> , 2016 , 4, 426	3.2	1
67	Hereditary Thrombophilias: Pathophysiology, Timing of Testing and Familial Testing 2016 , 475-484		1
66	Management of hemolyzed specimens. <i>Laboratornaya Sluzhba</i> , 2017 , 6, 38	0.1	1
65	Verification of the ACL Top 50 Family (350, 550, and 750) for Harmonization of Routine Coagulation Assays in a Large Network of 60 Laboratories. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 661-678 ^{1.9}		1
64	A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 1709-1718	5.9	1
63	Assessment of Plasma Sample Quality on Siemens Atellica COAG 360 System. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 315-318	5.3	1
62	Impact of water temperature on reconstitution of quality controls for routine hemostasis testing. <i>Diagnosis</i> , 2021 , 8, 233-238	4.2	1
61	Variability in D-dimer reporting revisited. <i>Pathology</i> , 2021 , 53, 538-540	1.6	1
60	Welcome to Seminars in Thrombosis & Hemostasis 2021-New (2019) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 1-5	5.3	1
59	Editorial Compilation IX. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 6-10	5.3	1
58	Diagnosis and management of von Willebrand disease in Australia. <i>Annals of Blood</i> , 2018 , 3, 31-31	0.6	1
57	2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12635	5.1	1
56	Commentary: Controversies in Thrombosis and Hemostasis Part 2-Does Sticky Platelet Syndrome Exist?. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 69-72	5.3	0

55	Myocardial Infarction, Unstable Angina, and White Thrombi: Time to Move Forward?. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 115-116	5.3	○
54	Hot Topics I: A Potpourri of Current Issues and Controversies in Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 723-726	5.3	○
53	Flow Cytometric Detection of Procoagulant Properties of Plasma from Patients with Clinically Confirmed Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Blood</i> , 2021 , 138, 3211-3211	2.2	○
52	Editorial Compilation X. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 754-758	5.3	○
51	Effect of sample heat inactivation on test levels of HIT-IgG detected by the ACL AcuStar. <i>Thrombosis Research</i> , 2021 , 200, 12-15	8.2	○
50	Plasma vs serum as test sample for the chemiluminescent AcuStar HemosIL HIT-IgG assay. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, e41-e44	2.5	○
49	Why is Misdiagnosis of von Willebrand Disease Still Prevalent and How Can We Overcome It? A Focus on Clinical Considerations and Recommendations. <i>Journal of Blood Medicine</i> , 2021 , 12, 755-768	2.3	○
48	Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2857-2861	15.4	○
47	Editorial Compilation XI.. <i>Seminars in Thrombosis and Hemostasis</i> , 2022 , 48, 127-131	5.3	○
46	Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12689	5.1	○
45	Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12676	5.1	○
44	"Von Willebrand disease type 2M: Correlation between genotype and phenotype": Comment from Favaloro.. <i>Journal of Thrombosis and Haemostasis</i> , 2022 , 20, 1019-1021	15.4	○
43	2021 Eberhard F. Mammen Award Announcements: Part II-Young Investigator Awards.. <i>Seminars in Thrombosis and Hemostasis</i> , 2022 , 48, 265-273	5.3	○
42	Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.. <i>Frontiers in Medicine</i> , 2022 , 9, 796109	4.9	○
41	Cell-Free DNA, Neutrophil extracellular traps (NETs), and Endothelial Injury in Coronavirus Disease 2019- (COVID-19-) Associated Acute Kidney Injury.. <i>Mediators of Inflammation</i> , 2022 , 2022, 9339411	4.3	○
40	Welcome to Seminars in Thrombosis & Hemostasis 2017 [New (2015) Impact Factor and Most Highly Cited Papers. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 001-003	5.3	○
39	2B or not 2B? A prothrombotic tendency masquerading as a bleeding disorder. <i>American Journal of Hematology</i> , 2017 , 92, 584-590	7.1	○
38	Welcome to Seminars in Thrombosis & Hemostasis 2015: New (2013) Impact Factor and Most Highly Cited Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 001-006	5.3	○

- 37 A holistic approach for the diagnosis of venous thromboembolism. *Journal of Laboratory and Precision Medicine*, **2020**, 5, 20-20 1.1
- 36 A retrospective analysis of correlation between APTT and anti-XA levels using ex vivo Plasma samples from patients on intravenous heparin therapy. *Pathology*, **2020**, 52, S115 1.6
- 35 Unfractionated heparin monitoring with activated partial thromboplastin time. *Pathology*, **2020**, 52, S36 1.6
- 34 Welcome to Seminars in Thrombosis & Hemostasis 2018. New (2016) Impact Factor and Most Highly Cited Papers. *Seminars in Thrombosis and Hemostasis*, **2018**, 44, 001-004 5.3
- 33 Mathematical rounding as a post-analytical issue in pathology reporting: generation of bias in INR resulting. *Pathology*, **2018**, 50, 459-461 1.6
- 32 Effect of contaminant 0.9% saline on tests of haemostasis. *Anaesthesia*, **2015**, 70, 1001-2 6.6
- 31 Commentary. *Clinical Chemistry*, **2015**, 61, 912 5.5
- 30 Artefactual "in-vitro coagulopathy" in a patient with non-Hodgkin lymphoma and lower gastrointestinal bleeding. *Medical Journal of Australia*, **2014**, 200, 293-4 4
- 29 Articles from Seminars in Thrombosis & Hemostasis (STH) Archives. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, A1-A1 5.3
- 28 Hot Topics V. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, 5-10 5.3
- 27 A Tribute to Professor Jerry Koutts, MD (Syd), BS, FRACP, FRCPA (1944-2013). *Seminars in Thrombosis and Hemostasis*, **2014**, 40, 001-004 5.3
- 26 Articles from Seminars in Thrombosis & Hemostasis (STH) Archives: Part II. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, A1-2 5.3
- 25 Welcome to Seminars in Thrombosis & Hemostasis 2014. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, 011-016 5.3
- 24 Diagnosis of von Willebrand Disease **2012**, 447-459
- 23 Welcome to Seminars in Thrombosis & Hemostasis 2013. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 005-009 5.3
- 22 Hot Topics IV. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 1-4 5.3
- 21 Global hemostasis: new approaches to patient diagnosis and treatment monitoring. Foreword. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 693-4 5.3
- 20 Under-recognized significance of endothelial heterogeneity: hemostasis, thrombosis, and beyond. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 223-4 5.3

- 19 Laboratory Evaluation of von Willebrand Disease: Phenotypic Analysis **2009**, 125-136
- 18 Welcome to the First Issue of Seminars in Thrombosis and Hemostasis for 2009. *Seminars in Thrombosis and Hemostasis*, **2009**, 35, 001-002 5.3
- 17 Relationship between activated partial thromboplastin time, heparin and potassium levels. *Diabetes Research and Clinical Practice*, **2009**, 83, e33-4 7.4
- 16 Cycling: to race or to live - reflections on skewed priorities?. *International Journal of Sports Medicine*, **2011**, 32, 648-9 3.6
- 15 Hormones, endocrine disorders, and hemostasis. *Seminars in Thrombosis and Hemostasis*, **2011**, 37, 3-5 5.3
- 14 Welcome to Seminars in Thrombosis & Hemostasis 2012. *Seminars in Thrombosis and Hemostasis*, **2012**, 38, 05-06 5.3
- 13 Genetic testing in von Willebrand disease: reply to rebuttal. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 861-862 15.4
- 12 Hot topics II: an editorial collection of current issues and controversies in thrombosis and hemostasis. *Seminars in Thrombosis and Hemostasis*, **2008**, 34, 3-6 5.3
- 11 Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone. *American Journal of Hematology*, **2002**, 70, 330-1 7.1
- 10 Welcome to Seminars in Thrombosis & Hemostasis 2022.. *Seminars in Thrombosis and Hemostasis*, **2022**, 48, 1-2 5.3
- 9 Laboratory Aspects in Diagnosis and Management of Venous Thromboembolism 35-48
- 8 Thrombin generation in different commercial sodium citrate blood tubes. *Journal of Medical Biochemistry*, **2020**, 39, 19-24 1.9
- 7 Laboratory Evaluation of Von Willebrand Disease: Phenotypic Analysis 192-203
- 6 Welcome to Seminars in Thrombosis & Hemostasis 2016: New (2014) Impact Factor and Most Highly Cited Articles. *Seminars in Thrombosis and Hemostasis*, **2016**, 42, 001-004 5.3
- 5 2B or not 2B? A diagnosis of von Willebrand disease a lifetime of 86 years in the making. *Blood Coagulation and Fibrinolysis*, **2021**, 32, 229-233 1
- 4 Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B. *Expert Opinion on Biological Therapy*, **2018**, 18, 95-100 5.4
- 3 45 years of Seminars in Thrombosis and Hemostasis. *Seminars in Thrombosis and Hemostasis*, **2018**, 44, 407-416 5.3
- 2 Platelet function testing: auditing local practice and broader implications. *Clinical Laboratory Science: Journal of the American Society for Medical Technology*, **2010**, 23, 21-31

- 1 Improving the inter-laboratory harmonization of the international normalized ratio (INR): utilizing the concept of transference to estimate and/or validate international sensitivity index (ISI) and mean normal prothrombin time (MNPT) values and/or to eliminate measurement bias. *Clinical Laboratory Science: Journal of the American Society for Medical Technology*, **2012**, 25, 13-25